Skip to content
Contact us
Oncology Splash
Metabolic Market Research for the GLP-1 Era & Beyond
 

Metabolic Market Research for the GLP-1 Era and Every Brand That Follows

GLP-1s have reshaped prescribing faster than any drug class in a generation. Oral contenders are in Phase 3, access barriers are blocking clinically preferred treatments, and HCPs are forming preferences weeks before they prescribe. ZoomRx helps pharma teams stay ahead of all of it.
Talk to a Metabolic Research Specialist

Why Generic Market Research Falls Short in Metabolic

Access barriers are blocking prescriptions your brand team doesn’t know about

Physicians are prescribing GLP-1s and patients are being turned away at the pharmacy. When access friction is this high, your commercial picture is incomplete without access intelligence built into the research.

Pipeline competition is moving faster than HCP awareness

More than half of HCPs are unaware of what’s entering their market in Phase 3. By the time your brand launches, competitor mechanisms may already own the awareness you need to displace.

HCPs decide before they prescribe and you’re not in the room

In metabolic, HCPs research treatment options weeks before writing a script. By the time your team sees a Rx shift, the mindshare battle is already over. Behavioral signals are the only early warning system.

Equal field force doesn’t produce equal outcomes

Lilly and Novo Nordisk had equal traditional rep reach, 42% share each in GLP-1 markets. Lilly still achieved higher HCP digital reach. In metabolic, digital execution separates winners from the field.

Research That Drives Your Next Decision, Not Just Your Next Report

Every ZoomRx metabolic program is built around the question your brand team is actually trying to answer from pre-launch positioning to in-market access optimization.

Brand Tracking (ATU)

Continuous HCP and patient tracking that goes beyond KPIs to actions — surfacing the shifts in awareness, prescription intent, and treatment satisfaction that tell your team what to do next, not just what happened.

Explore
Promotional Effectiveness Tracking (PET)
Fully custom research built around your brand, your HCPs, and your metabolic indication, not a syndicated panel applied to your data. The insight that tells you what’s working before your team commits the next wave of spend.

 

explore
Pre-Launch & Launch Intelligence
Research from Phase II through launch that answers the questions your team cannot afford to get wrong: which HCPs to prioritize, what barriers to expect, how your mechanism compares to what’s already in the market.

 

explore
Digital & Media tracking
Person-level HCP digital behavior tracking across ads, email, search, and medical platforms including the behavioral signals that reveal shifting brand attention weeks before prescription trends confirm them.

 

explore
HCP-Patient Conversations

HIPAA-compliant real-world research capturing what actually happens in diabetes and obesity consultations, including how HCPs navigate access conversations, treatment switching, and patient adherence at the point of care.

Explore
Ferma Congress Intelligence
Real-time coverage of ADA, ObesityWeek, EASD, and 250+ global conferences — so your team knows what moved prescribers before the week is out, not after the competitive response window has closed.

 

explore
Patient Chart Audits (PCA)
Voice-first AI capturing the treatment decision rationale behind GLP-1 prescriptions including why patients switch therapies, discontinue treatment, or face access barriers at the clinical level.

 

explore
INDICATIONS
Type 2 Diabetes Obesity / Weight Management MASH / NAFLD Cardiovascular Metabolic Prediabetes Rare Metabolic Disorders

What Makes ZoomRx Different in Metabolic Market Research

Onc-Icon 1
Insight you can act on, not just report on
 
ZoomRx doesn’t hand you a dashboard — we tell your team what the data means and what to do next. Every wave, every study, every congress readout is framed around your next commercial decision.
Onc-Icon 2
Custom research, not a syndicated tracker applied to your brand
 
Every ZoomRx oncology program is built around your specific HCPs, your indication, and your competitive set. That’s why brands switch to ZoomRx — and stay.
Onc-Icon 3
One team holds the full picture across your brand lifecycle
 
Pre-launch insight, brand tracking, promotional effectiveness, and patient research in one connected workflow. No fragmentation, no lost context between vendors.
Onc-Icon 4
AI that makes your research faster and sharper, not generic
 
Ferma surfaces what changed at ASCO, ASH, and ESMO before your team lands home. Message Labs tells you which messages will work before you deploy them. Human experts tell you what it means for your brand.
Onc-Icon 5
Oncology depth built on 80+ launches, not borrowed from other TAs
 
ZoomRx’s benchmarks come from real oncology research — across your indication, your launch stage, and your competitive context. Not cross-TA averages.

Explore Other Therapeutic Areas

ZoomRx delivers pharma market research across multiple therapeutic areas. Explore our research and capabilities by TA.
Oncology

HCP brand tracking, promotional effectiveness, manufacturer perception studies, and congress intelligence across 40+ indications.

Explore
CNS
Neurology, psychiatry, and rare neurological conditions. ZoomRx supports pre-launch intelligence and brand tracking across the full CNS indication landscape.

 

explore

Metabolic & GLP-1 Intelligence Published by ZoomRx

Blog-Cover
Metabolic Leaders and Specialty Drugs Drive Pharma’s Banner Ads in Q3 2025
read more
ASCO conference
ASCO 2025: ZoomRx 7th Annual Oncologist Survey
read more
FiercePharmaArticle
Enhertu, Keytruda Lead Oncology HCP Marketing — Fierce Pharma
read more

CTA

Talk to a Metabolic Research Specialist

Tell us about your brand and research challenge. We’ll connect you with a ZoomRx metabolic specialist who has worked across your indication, your competitive set, and your launch stage.

Get in touch

Frequently Asked Questions

How does ZoomRx track HCP behavior in metabolic markets beyond traditional Rx data?

ZoomRx’s Digital Tracker measures how long HCPs spend reviewing each brand across healthcare websites and how that attention shifts relative to competitors, a leading indicator that moves before prescribing habits change. ZoomRx tracked Zepbound’s rising attention in Q3 2024, months before revenue data confirmed its rise over Wegovy.

Which metabolic indications does ZoomRx research cover?

ZoomRx covers type 2 diabetes, obesity and weight management, cardiovascular metabolic conditions, and MASH/NAFLD. Research spans the full prescriber base, endocrinologists, primary care physicians, cardiologists, and obesity medicine specialists, depending on where your brand competes.

How do you choose a metabolic market research partner?

Look for a partner that integrates leading indicators - HCP digital attention, access barrier data with traditional brand tracking in one workflow, and uses benchmarks built from real metabolic data, not cross-TA averages. ZoomRx does all three, with a dedicated metabolic practice that tracked Zepbound's market momentum months before prescription data confirmed it.